Predicting treatment dropout after antidepressant initiation
| Autor: | Roy H. Perlis, Melanie F. Pradier, Finale Doshi-Velez, Michael C. Hughes, Thomas H. McCoy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Depressive Disorder Not Otherwise Specified Venlafaxine Article lcsh:RC321-571 law.invention 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Randomized controlled trial law Internal medicine Humans Psychology Medicine Escitalopram Longitudinal Studies 030212 general & internal medicine lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Biological Psychiatry Retrospective Studies Depressive Disorder Major Depression business.industry medicine.disease Paroxetine Antidepressive Agents 3. Good health Discontinuation Psychiatry and Mental health Tolerability Major depressive disorder business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Translational Psychiatry, Vol 10, Iss 1, Pp 1-8 (2020) Translational Psychiatry |
| ISSN: | 2158-3188 |
| DOI: | 10.1038/s41398-020-0716-y |
| Popis: | Antidepressants exhibit similar efficacy, but varying tolerability, in randomized controlled trials. Predicting tolerability in real-world clinical populations may facilitate personalization of treatment and maximize adherence. This retrospective longitudinal cohort study aimed to determine the extent to which incorporating patient history from electronic health records improved prediction of unplanned treatment discontinuation at index antidepressant prescription. Clinical data were analyzed from individuals from health networks affiliated with two large academic medical centers between March 1, 2008 and December 31, 2014. In total, the study cohorts included 51,683 patients with at least one International Classification of Diseases diagnostic code for major depressive disorder or depressive disorder not otherwise specified who initiated antidepressant treatment. Among 70,121 total medication changes, 16,665 (23.77%) of them were followed by failure to return; maximum risk was observed with paroxetine (27.71% discontinuation), and minimum with venlafaxine (20.78% discontinuation); Mantel–Haenzel χ2 (8 df) = 126.44, p = 1.54e–23 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|